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Abstract
Background: Gram-positive and Gram-negative bacteria are main causes of pneumonia or acute lung injury. They are
recognized by the innate immune system via toll-like receptor-2 (TLR2) or TLR4, respectively. Among all organs, the lungs
have the highest expression of TLR2 receptors, but little is known about the pulmonary consequences of their activation.
Here we studied the effects of the TLR2/6 agonist MALP-2, the TLR2/1 agonist Pam3Cys and the TLR4 agonist
lipopolysaccharide (LPS) on pro-inflammatory responses in isolated lungs.
Methodology/Principal Findings: Isolated perfused mouse lungs were perfused for 60 min or 180 min with MALP-2 (25 ng/
mL), Pam3Cys (160 ng/mL) or LPS (1 mg/mL). We studied mediator release by enzyme linked immunosorbent assay (ELISA),
the activation of mitogen activated protein kinase (MAPK) and AKT/protein kinase B by immunoblotting, and gene
induction by quantitative polymerase chain reaction. All agonists activated the MAPK ERK1/2 and p38, but neither JNK or
AKT kinase. The TLR ligands upregulated the inflammation related genes Tnf, Il1b, Il6, Il10, Il12, Ifng, Cxcl2 (MIP-2a) and
Ptgs2. MALP-2 was more potent than Pam3Cys in inducing Slpi, Cxcl10 (IP10) and Parg. Remarkable was the strong
induction of Tnc by MALP2, which was not seen with Pam3Cys or LPS. The growth factor related genes Areg and Hbegf were
not affected. In addition, all three TLR agonists stimulated the release of IL-6, TNF, CXCL2 and CXCL10 protein from the
lungs.
Conclusions/Significance: TLR2 and TLR4 activation leads to similar reactions in the lungs regarding MAPK activation, gene
induction and mediator release. Several genes studied here have not yet been appreciated as targets of TLR2-activation in
the lungs before, i.e., Slpi, tenascin C, Parg and Traf1. In addition, the MALP-2 dependent induction of Tnc may indicate the
existence of TLR2/6-specific pathways.
Citation: Barrenschee M, Lex D, Uhlig S (2010) Effects of the TLR2 Agonists MALP-2 and Pam3Cys in Isolated Mouse Lungs. PLoS ONE 5(11): e13889. doi:10.1371/
journal.pone.0013889
Editor: Dominik Hartl, Ludwig-Maximilians-Universita ¨tM u ¨nchen, Germany
Received October 13, 2009; Accepted October 15, 2010; Published November 16, 2010
Copyright:  2010 Barrenschee et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by the Deutsche Forschungsgemeinschaft (Bonn, Germany) within the Sonderforschungsbereich SFB 542 TPC16. The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: suhlig@ukaachen.de
Introduction
Toll-like receptors play a critical role in the recognition of
pathogens by the innate immune system [1,2]. Gram-positive
bacteria are recognized by TLR2 receptors by their signature
lipoproteins/lipopeptides [3]. Among all organs, the lungs have
the highest expression of TLR2 receptors [4]. Beyond infection
[5–7], TLR2-receptors may play a role in several pulmonary
diseases including fibrosis [8], asthma [9], lung contusion [10] and
acute lung injury [11], as suggested by studies in TLR2-deficient
mice. Polymorphisms in the Tlr2 gene have been associated with
susceptibility to tuberculosis [12]. TLR2 forms heterodimers with
either TLR1 or TLR6 and polymorphisms in these receptors have
been associated with atopic asthma [13] and organ dysfunction in
sepsis [14]. For some time, lipoteichoic acid (LTA) was considered
a relevant TLR2 receptor ligand, and most studies on TLR2
receptors in the lungs have focused on this agent [e.g. in 15–18].
However, because recent evidence indicates that LTA is not a
TLR2 receptor ligand [3], now only little is known about the
effects of true TLR2 ligands in the lungs. Two well defined ligands
that permit studying the functions of TLR2 receptors are the
lipopetides Pam3CSK4 and MALP-2, containing three and two
fatty acids, respectively [3].
Macrophage-activating lipopeptide 2 KDa (MALP-2) was
originally isolated from Mycoplasma fermentas [19] and is now
available synthetically. It uses CD36 as a coreceptor and signals by
TLR2/TLR6 heterodimers [20]. In vivo, MALP-2 causes increased
BAL levels of several pro-inflammatory cytokines and chemokines
as well as neutrophil and lymphocyte infiltration [21,22]. In
murine precision-cut lung slices (PCLS), it had no effect on
cytokine release unless it was applied together with interferon c,i n
whose presence it increased TNF and IL-1a release [23], whereas
in human PCLS and in human airway epithelial cells MALP-2 or
an analogon induced several cytokines and chemokines after 24h
[24,25]. Notably, pulmonary application of MALP-2 improved
metastasis [26], vaccination [27] and survival in pneumonia [22].
The synthetic bacterial lipopeptide analogon Pam3CysSK4 (in
the following referred to as Pam3Cys) acts on TLR1/TLR2
heterodimers [3] In intact lungs it caused cytokine and chemokine
release [28], and in human bronchial epithelial cells (hBE) and
human alveolar macrophages it stimulated release of TNF, IL-1,
IL-6 and IL-8 [29,30]. There is evidence that TLR1 and TLR6-
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associated with higher mortality rates in sepsis and hyperrespon-
siveness towards Pam3Cys [14].
Thus, recent evidence is indicating that both MALP-2 [22] and
Pam3Cys [28] can stimulate cytokine and chemokine release in the
lungs. However, as these studies where done in vivo the
contribution of lung parenchyma versus recruited cells to these
responses remains unknown. Furthermore, as these ligands
stimulate TLR2-receptors differently, i.e. either TLR2/TLR1
heterodimers (Pam3Cys) or TLR2/TRL6 heterodimers, the
relative potency and specificity of these agents with respect to
pro-inflammatory responses in the lungs is unknown. Therefore, to
systematically compare the effects of TLR2/TLR1 vs. TLR2/
TLR6 in lung tissue independent of recruited leukocytes, we used
isolated blood-free perfused mouse lungs to study the effects of
MALP-2 and Pam3Cys and compared them to those of the well
known TLR4 ligand lipopolysaccharide.
Results
Lung physiology
As reported before [31], LPS administration did not change
pulmonary lung functions in isolated perfused mouse lungs (Fig. 1).
Likewise, neither MALP-2 nor Pam3Cys administration signifi-
cantly altered tidal volume or pulmonary resistance, their values
always being between 0.3 to 0.4 mL and 0.2 to 0.3 cm
H2O?s?mL
21, respectively.
MAP and Akt kinase
Since TLR2 is well known to activate MAPK pathways [32], we
analyzed activation of ERK1/2, JNK and p38. In addition, we
also examined phosphorylation of AKT kinase (protein kinase B).
After 60 min, both Pam3Cys and MALP-2 increased the
phosphorylation of ERK1/2 and p38 compared to controls,
whereas JNK and AKT kinase were not affected (Fig. 2). After,
180 min treatment, both TLR2 ligands and also the TLR4 ligand
LPS appeared to increase the phosphorylation of p38 and ERK1/
2, although these effects were no longer significant. Again,
increased phosphorylation of JNK or AKT kinase was not
observed.
Gene expression
We investigated the regulation of 3 genes related to cell growth
or differentiation, and an additional 15 genes involved in
inflammatory processes. These growth factors and tenascin C
(Tnc) were studied because they were found to be upregulated by
another potent cause of pulmonary inflammation, i.e. high tidal
volume ventilation [33]. The genes were selected for their well
known role in a wide variety of inflammatory processes in the lung,
i.e. cyclooxygenase 2 (Ptgs2, [34]), poly(ADP-ribose)glycohydro-
lase (Parg, [35]), secretory leukoprotease inhibitor (Slpi, [36]),
Traf1, [37]), IP10 (Cxcl10, [38]), interleukin 1b (Il1b, [39]), MIP-
2a (Cxcl2, [40]), interleukin-4 (Il4, [13]), interleukin-6 (Il6, [40]),
interleukin-10 (Il10, [41]) interleukin-12 (Il12a, i.e. IL12p35;
Il12b,i.e. IL12p40, [42]), interferon c (Ifng, [43]) and tumor
necrosis factor (Tnf, [40]). Gene selection was also based on the
distinction that has been made between Myd88-dependent (Tnf,
Il1b, Il6), and TRIF-dependent (Traf1, Cxcl10) gene expression
[44].
The gene expression patterns were analyzed by cluster analysis
(Fig. 3) and revealed four major clusters based on the intensity of
their expression in response to the different TLR ligands. The data
are presented in accordance with these clusters in the figures 4 to
6. Please note that the Y-axis is the same in each subpanel of one
figure, but differs between the figures.
Cluster 1 (red in Fig. 3, Fig. 4): No or only weakly increased
expression. This cluster contained the growth factors angiopoietin-
like 2, HB-EGF and amphiregulin that remained unaltered, Parg
and Traf1 that were about two-fold upregulated by MALP-2 and
Slpi that was about two-fold upregulated by MALP-2 and LPS,
but not by Pam3Cys.
Cluster 2 (brown in Fig. 3, Fig. 5). This cluster contained genes
that were upregulated between 2.5-fold and about 10-fold. Il4,
Il12a, Il10 and Ptgs2 were upregulated by all TLR ligands; Cxcl10
was upregulated by both MALP-2 and LPS, and Tnc was strongly
upregulated by MALP-2 alone.
Group 3 and 4: (green and blue in Fig. 3, Fig. 6). This cluster
contains genes for inflammatory proteins, that were strongly (.5-
fold) upregulated under all conditions. These genes, i.e. Il1b,
Cxcl2, Il6, Tnf, Ifng and IL12p40 (IL12b) showed comparably
strong mRNA expression levels (between 5–15 fold increases) in
lung tissue upon TLR2 or TLR4 receptor stimulation, indicating
that the concentrations chosen were about equipotent with respect
to their pro-inflammatory capacity (Fig. 6).
With respect to differences between MALP-2 and Pam3Cys we
noted that Cxcl10 and Slpi were strongly increased by MALP-2
and LPS, but comparatively little by Pam3Cys. Three genes were
significantly stimulated by MALP-2 only, i.e. Tnc, Parg and Traf1.
Figure 1. Lung functions. (A) Tidal volume and (B) pulmonary resistance in isolated perfused mouse lungs exposed to Pam3Cys (160 ng/mL, black
squares), MALP-2 (25 ng/mL, grey squares) or LPS (1 mg/mL, black circles) from 60 min to the end of the experiment; control lungs are shown as
white circles. Data are expressed as mean 6 SEM, n=3–5.
doi:10.1371/journal.pone.0013889.g001
TLR2 Agonists in the Lung
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The time course of the release of two cytokines (IL-6, TNF) and
two chemokines (MIP-2a, IP10) into the perfusate was measured by
ELISA (Fig. 7). As all lungs were perfused with 1 mL/min in a non-
recirculating fashion, the concentrations given on the ordinate
represent the pulmonary production within 1 minute. The IL-6
production was comparable between all three TLR-ligands. For
TNF, MIP-2a and IP10, LPS was always the most potent stimulus,
b u tt h eT L R 2a g o n i s t sw e r ee f f e c t i v ea sw e l l .T h et i m ec o u r s eo f
release was the same for IL-6, TNF and MIP-2a with production
setting in about 60 min after addition of the stimulus. IP-10
production did not start before 120 min after addition of the stimulus.
Discussion
Gram-positive bacteria present a severe health burden and are a
major cause of community acquired pneumonia [45] and acute
lung injury [14,46]. Hence it may not be a coincidence that among
Figure 2. Mitogen activated protein kinase and Akt kinase activation. After 60 min of perfusion under baseline conditions, isolated mouse
lungs were perfused for another 60 or 180 min with Pam3Cys (160 ng/mL, n=5), MALP-2 (25 ng/mL, n=5), LPS (1 mg/mL, n=3) or under control
conditions (n=5). The basal and phosphorylated forms of several kinases were analyzed by immunoblotting after 60 min or 180 min: (A) Erk1/2, (B)
p38, (C) Jnk, and (D) Akt kinase. Data were calculated as the ratio of the phosphorylated protein to the total amount of the protein and then
referenced to the control on the same gel. Data are shown as mean 6 SEM. The micrographs show one representative immunoblot from 3 (LPS) or 5
(C; Pam3Cys, MALP-2) independent experiments.
doi:10.1371/journal.pone.0013889.g002
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TLR2, the receptor for recognition of Gram-positive bacteria [4].
Here, we compared the responses of isolated lungs to stimulation
of TLR2/TLR1, TLR2/TLR6 and TLR4 receptors by using
highly purified ligands in order to exclude unspecific effects.
Several genes studied here have not yet been appreciated as targets
of TLR2-activation in the lungs before, i.e. Slpi, tenascin C,
poly(ADP-ribose)glycohydrolase and Traf1. Our findings suggest
that all three receptor systems cause similar responses in the lungs
with respect to MAP kinase activation, gene induction and
mediator release. Of note, TLR2-ligation induced both Myd88-
dependent (TNF, IL-1b, IL-6) and TRIF-dependent (Traf1, IP10)
genes. In contrast to the other genes, tenascin C was upregulated
by MALP-2, but not by LPS, suggesting the possibility of TLR2-
specific signaling pathways in the lungs. Because of perfusion with
blood-free buffer, all these responses occurred independent of
sequestered leukocytes. On the other hand, the failure of the TLR
ligands to cause overt changes in tidal volume or airway resistance
supports the notion that effects on physiological lung functions in
vivo depend on the sequestration of leukocytes.
The present observations on the gene induction and production
of IL-6, MIP-2a and TNF confirm previous findings in mouse
lungs perfused with LPS [33,40] and indicate that TLR2 receptor
activation leads to similar responses as that of TLR4 receptors.
Together with IL-1b these cytokines represent typical genes that
are activated by the Myd88-dependent signaling pathway [44],
although MIP-2a may also be activated by TRIF [47]. The
activation of Myd88-dependent pathways is also supported by the
activation of Erk and p38, similar to previous findings in airway
epithelial cells, alveolar macrophages [48,49] and intact lungs
[50]. Corroborating results with LPS [51], TLR2 ligands failed to
activate Akt in isolated lungs; thus the activation of Akt that is
caused by LPS in vivo [50] is probably related to the
phosphorylation of Akt in sequestered leukocytes [52].
The increase in IP10 gene and protein levels by TLR2 ligation
(Fig. 5, Fig. 7,[24]) – although not as strong as with LPS – is
somewhat unexpected, since IP-10 is typically considered to
depend on TRIF which according to present knowledge does
couple to TLR4 but not TLR2 receptors. In addition, MALP-2
was even stronger than LPS in inducing another TRIF-dependent
gene, namely Traf1. As an explanation, contamination of the
MALP2 with LPS seems unlikely, because both MALP-2 and
Pam3Cys were synthetically produced and perfused at concentra-
tions several times lower than LPS – concentrations at which LPS
shows little effect in our system [31; and unpublished observa-
tions]; furthermore, it is well known that in the nanomolar range
LPS is inactive in the absence of lipopolysaccharide binding
protein [53]. More likely explanations for the activation of IP10
and Traf1 by TLR2 agonists are: (i) The production of IP10
started later than that of the other cytokines; thus it seems possible
that IP10 was induced by other cytokines such as IL-1b, TNF or
IFNc [38]. (ii) There might exist some small Myd88-dependent
part in MALP-2-induced activation of IP10 [54] or even another
TRIF-independent pathway that is activated by MALP-2; (iii)
Many studies on the role of TRIF in the expression of IP10 or
Traf1 have been performed in myeloid or fibroblast cells in
culture. However, TRIF expression is particularly abundant in the
lungs [4], and there are cell-type and organ-specific differences in
Figure 3. Cluster analysis of the gene expression data. After 60 min of perfusion under baseline conditions, isolated mouse lungs were
perfused for another 180 min with Pam3Cys (160 ng/mL, n=5), MALP-2 (25 ng/mL, n=5), LPS (1 mg/mL, n=3) or under control conditions (n=5). The
different colors (red, brown, green, blue) identify genes that clustered together.
doi:10.1371/journal.pone.0013889.g003
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2-dependent release of IP10 had been observed before in human
airway epithelial cells in culture [24]. Of interest, in another recent
study Pam3Cys was able to strongly induce RANTES – another
TRIF-dependent cytokine – in human airway epithelial cells [48].
Collectively, these studies suggest that the distinction between
Myd88-dependent and TRIF-dependent genes is not helpful to
predict mediator production from intact organs that consist of
many different cell types. Nonetheless, in future studies it would be
of great interest to learn which pulmonary cell type is responsible
for the production of specific cytokines in situ.
Because TLR1 and TLR6-receptors do not appear to be
redundant [14], one aim of the present study was to compare the
consequences of TLR2/TLR1 vs. TLR2/TRL6 receptor activa-
tion in the lungs. Therefore, we have employed Pam3Cys that
signals through TLR2/TLR1 heterodimers and MALP-2 that
signals through TLR2/TRL6 receptors. The concentrations
required for pro-inflammatory signaling were relatively low for
perfusion experiments in intact lungs, i.e. 25 ng/mL for MALP-2
and 160 ng/mL for Pam3Cys. At these concentrations, both
TLR2 ligands showed a strong pro-inflammatory response.
Overall the responses to both TLR2 ligands on MAP kinases,
gene expression and mediator production were similar. However,
MALP-2 was able to induce the expression of three genes that
were not affected by Pam3Cys, i.e. Slpi, Tnc and Parg. As these
genes had not before been studied following TLR2 receptor
activation, the significance of these findings remains to be shown.
Others have reported in candidiasis that TLR1 deficient mice had
no altered phenotype, whereas TLR6-deficient mice produced
similar levels of TNF, IL-1 and IL-6, but less IFNc and IL-10,
providing further evidence that some genes may be regulated
specifically by TLR2/TLR6-receptor heterodimers [57], although
from thorough studies in cell culture it was concluded that TLR1
and TLR6 lead to identical signaling events [58].
The pattern of gene transcription was very similar between the
three TLR-receptor agonists studied and all of them induced
several genes that are known to be involved in inflammation (see
Fig. 5,6). It should also be noted that agonists of TLR-ligands such
as the agents that were studied here, may amplify their own
responses by upregulation of TLR-receptors [59–61], although the
pathophysiological significance of this response in the lungs
remains to be further established [62,63]. Two observations may
Figure 4. Expression of genes in cluster 1. After 60 min of perfusion under baseline conditions, isolated mouse lungs were perfused for another
180 min with Pam3Cys (160 ng/mL, n=5), MALP-2 (25 ng/mL, n=5), LPS (1 mg/mL, n=3) or under control conditions (n=4). Genes: amphiregulin
(Areg), angiopoietin-like 2 (Angptl2), heparin-binding epithelial growth fator (HBegf), poly(ADP-ribose)glycohydrolase (Parg), TNF receptor-associated
factor 1 (Traf1), and secretory leukocyte peptidase inhibitor (Slpi). Data were normalized to the experimental control and are shown as mean 6 SEM.
*, p,0.05 vs control; **, p,0.01 vs control; ***, p,0.001 vs control.
doi:10.1371/journal.pone.0013889.g004
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amphiregulin (Areg) and heparin-binding EGF-like growth factor
(Hbegf) that are well known to be activated by mechanical stimuli
[33,64], were not affected by TLR2 or TLR4-receptor activation.
This is noteworthy, because otherwise most of the genes that are
activated by LPS in the lungs are also activated by mechanical
ventilation [33,65–67], suggesting that amphiregulin and HB-EGF
may be used as molecular markers to distinguish infectious from
mechanical stimuli. Second, tensascin C, an extracellular matrix
(ECM) glycoprotein within the tenascin familiy [68] was highly
upregulated by MALP-2 (Fig. 4). Tenascin C harbors an EGF-like
domain [68], and shows low but detectable action on the EGF-
receptor [69]. It is highly expressed in lungs from patients with
respiratory distress syndrome and bronchopulmonary dysplasia,
although its role in the pathogenesis of these ailments is unknown
[70]. In general, tenascins are thought to be involved in tissue
remodeling after injury [71], providing a possible explanation for
the beneficial effects of MALP-2 on wound healing in mice [72]
and humans [73].
In conclusion, TLR1/2-, TLR 2/6- and TLR4-specific ligands
induced Th1-cytokines (Tnf, Ifng, Il12), Th2 cytokines (Il4)
and anti-inflammatory genes (Slpi, Il10). Despite the fact that
TLR2-receptors do not couple to TRIF, the effects of TLR2/1,
TLR2/6 and TLR4-receptor activation in the isolated lungs on
MAPK activation, gene induction and cytokine release were
largely similar. In addition to several well known pro-inflamma-
tory cytokines we also demonstrate TLR2-dependent production
of IP10, a chemokine which is upregulated in acute lung injury
[74], although its functions in this setting remain poorly defined.
Other genes shown to be upregulated by TLR2-receptor
activation were Slpi, tenascin C, poly(ADP-ribose)glycohydrolase
and Traf1. Particularly impressive and restricted to MALP-2
(TLR2/6) was the induction of tenascin C suggesting the existence
of TLR2/6-specific pathways.
Materials and Methods
Animals and reagents
Female BALB/C mice were obtained from Harlan Laboratories
(The Netherlands). All animals were used at a weight of 20 to 25 g.
Care and handling of the animals was performed in accordance
with the regional committee of animal experimentation ethics.
HES-buffer for isolated perfused mouse lungs was custom-made
by SERAG-Wiessner (Naila, Germany). Primary antibodies were
Figure 5. Expression of genes in cluster 2. After 60 min of perfusion under baseline conditions, isolated mouse lungs were perfused for another
180 min with Pam3Cys (160 ng/mL, n=5), MALP-2 (25 ng/mL, n=5), LPS (1 mg/mL, n=3) or under control conditions (n=5). Genes: interleukin 4 (Il4),
interleukin 12p35 (Il12a), tenascin C (Tnc), interleukin 10 (Il10), cyclooxygenase 2 (Ptgs2), and IP10 (Cxcl10). Data were normalized to the experimental
control and are shown as mean 6 SEM. *, p,0.05 vs control; **, p,0.01 vs control; ***, p,0.001 vs control.
doi:10.1371/journal.pone.0013889.g005
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Germany), the secondary ones (goat-anti mouse IRDye800CW,
goat-anti rabbit IRDye 680) for fluorescence detection with the
ODYSSEY-System (LI-COR, Bad Homburg) were purchased
from LI-COR. Primers for RT-qPCR were synthesized and
purified by MWG (Ebersberg, Germany). All other chemicals and
substances used were of analytical grade and commercially
available. Pam3CysSK4 was from EMC microcollections (Tu ¨bin-
gen, Germany), MALP-2 from Alexis Biochemicals (Gru ¨nberg,
Germany). Highly purified lipopolysaccharide from S. abortus equii
[75] was kindly provided by Helmut Brade (Research Center
Borstel, Borstel, Germany).
Isolated perfused mouse lung preparation (IPL)
The mouse lungs were prepared and perfused as described
[76,77], with small modifications in the buffer (4% hydroxyl ethyl
starch instead of 4% BSA).
All lungs were perfused at 1 mL/min and ventilated for 60 min
under control conditions with an end-inspiratory pressure (EIP) of
-10 cm H2O and an end-expiratory pressure (EEP) of -3 cm H2O,
resulting in tidal volumes of about 300 mL and perfused and
stimulated either for another 60 min (experimental set 1) or
180 min (experimental set 2).
Set 1: After 60 min, the lungs were randomly allocated to one of
the following four groups and perfused and ventilated for another
60 min: group 1 under control conditions, group 2 with addition
of 160 ng/mL (100 nM) Pam3CysSK4 and group 3 with
25 ng?mL
21 MALP-2.
Set 2: After 60 min, the lungs were randomly allocated to one of
the following four groups and perfused and ventilated for another
180 min: group 1 under control conditions, group 2 with 160 ng/
mL Pam3CysSK4, group 3 with 25 ng/mL MALP-2, group 4 with
1 mg/mL lipopolysaccharide (LPS) from S. abortus equii. After
ventilation, the surrounding tissue, the heart, and the trachea were
trimmed away, subsequently lungs were flash frozen under liquid
nitrogen and stored at -80uC.
Immunoblotting
Aliquots of 30 mg lung powder were lysed and homogenized in
cell extraction buffer (Biosource), containing 1 mM PefaBlock
(Roche-Diagnostics) and complete mini (Roche-Diagnostics)
according to manufacturer’s instructions.
Figure 6. Expression of genes in cluster 3 and 4. After 60 min of perfusion under baseline conditions, isolated mouse lungs were perfused for
another 180 min with Pam3Cys (160 ng/mL, n=5), MALP-2 (25 ng/mL, n=5), LPS (1 mg/mL, n=3) or under control conditions (n=5). Genes:
interleukin 1b (Il1b), macrophage inflammatory protein 2a (Cxcl2), interleukin 6 (Il6), tumor necrosis factor (Tnf), interferon c (Ifng), and IL12p40
(IL12b). Data were normalized to the experimental control and are shown as mean 6 SEM. *, p,0.05 vs control; **, p,0.01 vs control; ***, p,0.001 vs
control.
doi:10.1371/journal.pone.0013889.g006
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1 8 0m i nw i t hP a m 3Cys (black squares, 160 ng/mL, n=5), MALP-2 (grey squares, 25 ng/mL, n=5), LPS (black circles, 1 mg/mL, n=3) or under control conditions
(white circles, n=4). Perfusate samples were taken every 30 min and analyzed by ELISA for TNF (A), IL-6 (B), MIP-2a (C)a n dI P - 1 0( D). Data are expressed as
mean 6 SEM. *, p,0.05 vs. control.
doi:10.1371/journal.pone.0013889.g007
Table 1. Primer for mouse-target genes used in quantitative-real-time PCR (qPCR).
target gen primer (sense) primer (antisense)
Angptl2 59-GAGAATACCAACCGCCT-39 59- ATAGGTCTCCCAGTTCC-39
Hbegf 59-GTGTTGTCCGCGTTGGT-39 59- TGTCCCTTCCAAGTCCT-3
Areg 59-CTATCTTTGTCTCTGCCATCA-39 59-AGCCTCCTTCTTTCTTCTGTT-39
Parg 59-GTGACTGTTCGGGTAGAC-39 59- GTTCGCTCACCATTCTCATC-39
Traf1 59-TGAGAACCTGAGAGATGATG-39 59- TGAAGGAACAGCCAACACC-39
Slpi 59-TGAGAAGCCACAATGCCG-39 59- CACTGGTTTGCGAATGGG-39
Cxcl10 59-GCCGTCATTTTCTGCCTCAT-39 59-GCTTCCCTATGGCCCTCATT-39
Ptgs2 59-AGATGACTGCCCAACTCCCAT-39 59-CAGGGATGAACTCTCTCCGTA-39
Tnc 59-CTTCATTCGTGTGTTCGCCA-39 59-ATCCCACTCTACTTCCACAG-39
Il1b 59-GAAAGCTCTCCACCTCAATG-39 59-GCCGTCTTTCATTACACAGG-39
Cxcl2 59-AGTGAACTGCGCTGTCAATGC-39 59-AGGCAAACTTTTTGACCGCC-39
Il6 59-CCAGAGATACAAAGAAATGATGG-39 59-ACTCCAGAAGACCAGAGGAAA-39
Tnf 59-TCTCATCAGTTCTATGGCCC-39 59-GGGATGAGACAAGGTACAAC-39
Tyk2 59-AGTGTTCTGGTATGCCC-39 59- TGGTTAGAGTCACAGTATG-39
B2m 59-TGACCGGCTTGTATGCTATC-39 59-CAGTGTGAGCCAGGATATAG-39
Rp32 59-AGCGAAACTGGCGGAAAC-39 59- GACCAGGAACTTGCGGAA-39
Hprt1 59-TTATGGACAGGACTGAAAGA-39 59-TGTAATCCAGCAGGTCAGCA-39
Ifng 59-GAGGTCAACAACCCACAGGTC-39 59- CGAATCAGCAGCGACTCCT-39
Il10 59-GAAGACCCTCAGGATGCG-39 59-GCCTTGTAGACACCTTGGTC-39
Il12a 59-TGTCAATCACGCTACCTCCTC -39 59-TCGGGACTGGCTAAGACAC-39
Il12b 59-CAAGAGCAGTAGCAGTTCCC-39 59-GGTCCAGTGTGACCTTCTCT-39
Il4 59-GTCATCCTGCTCTTCTTTCTC-39 59-TCTCTGTGGTGTTCTTCGT-39
doi:10.1371/journal.pone.0013889.t001
TLR2 Agonists in the Lung
PLoS ONE | www.plosone.org 8 November 2010 | Volume 5 | Issue 11 | e13889After 30 min on ice, lysates were collected by pelleting the
cellular debris for 10 min at 16.0006g. Total protein content was
determined by BCA Protein Assay Kit (Pierce, Rockford, USA).
Equal amounts of protein (30 mL/slot) were size fractionated by
sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophore-
sis, transferred to nitrocellulose transfer membranes (Protran,
Schleicher & Schuell, Dasel,Germany) and immunoblotted with
primary antibodies that are specific for the phosphorylated and
non-phosphorylated form of the investigated protein (Cell
Signaling Technology CST (Frankfurt, Germany).
After incubating and washing, nitrocellulose membranes were
incubated with both secondary fluorescence labelled antibodies (LI-
COR, Bad Homburg). Detection and quantification was realized
using the OdysseyH infrared imaging system by LI-COR (Lincoln,
Nebraska USA). Protein bands were pictured at 700 nm and
800 nm simultaneously in a single scan, using the Odyssey Infrared
Imaging system (LICOR, Bad Homburg, Germany). Specific
protein bands were quantified with Odyssey imaging software.
Integrated intensities of specified bands were expressed as ratio of
the phosphorylated to the non-phosphorylated form of the detected
protein; protein expression is expressed as fold increase relative to
controls.
Reverse transcriptase quantitative real time PCR
(RT-qPCR)
Total RNA from 30 mg lung powder were isolated with
NucleoSpinH RNA II Kit according to manufacturer’s instructions
(Machery Nagel, Du ¨ren, Germany). 8 mL total RNA was
completed with 2 mL Oligo-(dt)-primer (Invitrogen, Karlsruhe,-
Germany), mixed, centrifuged and subsequently incubated at
65uC for 10 min to linearize RNA. 2 mL of this RNA-primer-mix
were added to 1 mL Superscript II
TM Reverse Transcriptase
(200 U/mL) (Invitrogen), 4 ml 5x Strand Puffer (250 mM Tris/
HCl, ph 8.3; 375 mM KCl,15 mM MgCl2) (Invitrogen), 2 mL
DTT (0.1M) (Invitrogen), 2 ml dNTP-Mix (10 mM) (peqLAB,
Erlangen), 1 mL RNaseOut (40 U/mL) (Invitrogen) and incubated
for 90 min at 37uC. Afterwards, the mixture was diluted with
30 mLH 2O and real-time qPCR product accumulation was
monitored in a Light-Cycler480 (Roche-Diagnostics) using 1 mLo f
total cDNA, 312.5 nM forward, 312.5 nM reverse primer and
SYBR-Green I Mastermix (Roche-Diagnostics, Mannheim, Ger-
many) according to manufacturer’s instructions. The primers are
shown in Table 1. The data were normalized first to the Tyk2
gene (see next paragraph); gene expression is expressed as fold
induction relative to controls.
Reference genes, often also referred to as calibrator genes are
used to normalize RNA levels between different samples.
However, since their expression level may vary among tissues,
cells and treatment conditions, the selection of a useful reference
gene is critical [78]. In our studies in isolated and ventilated
perfused mouse lungs, we investigated the expression of three
commonly used housekeeping genes b2 microglobulin (B2m),
ribosomal protein L 32 (Rpl32) and hypoxhantine phosphoribosyl
transferase I (Hprt1), and in addition also of tyrosine kinase 2
(Tyk2). Among these, only tyrosine kinase 2 (Tyk2) did not differ
between the treatment groups and was therefore chosen as the
reference gene for RT-qPCR (Fig. 8).
Cytokine concentration in the perfusate
For detection of TNF, IL-6, MIP-2a and IP-10 in perfusate
samples, commercially available tests (OptEIATM Set Mouse
TNF (mono/poly), OptEIATM Mouse IL-6 Set, BD Biosciences,
San Diego, CA, USA, Quantikine Mouse MIP-2 Immunoassay,
R&D Systems GmbH, Wiesbaden, Germany and the CXCL10
DuoSet ELISA Kit, R&D Systems) were purchased and
performed exactly according to the manufacturer’s instructions.
Statistics
Data were analyzed with JMP 7.0.1 for windows, and expressed
as mean 6 standard error (SEM). Data were always transformed
by the Box-Cox transformation and examined by two-sided
student’s t-test. Homoscedasticity was confirmed by the Levene-
test. P-values were corrected for multiple comparisons according
to the false-discovery rate procedure, using R 2.8.0 [33]. p,0.05
vs control was considered significant. Cluster analysis were
performed in JMP 7.0.1, using the Complete clustering method
with normalized RT-qPCR data.
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Figure 8. Reference genes for RT-qPCR experiments. After
60 min of perfusion under baseline conditions, isolated mouse lungs
were perfused for another 180 min with Pam3Cys (160 ng/mL, n=5),
MALP-2 (25 ng/mL, n=5), LPS (1 mg/mL, n=3) or under control
conditions (n=4). Shown are four potential callibrator genes: b2-
microglobulin (b2m), ribosomal protein L 32 (rpl32), hypoxhantine
phosphoribosyl transferase I (hprt1) and tyrosine kinase 2 (tyk2). Data
were normalized to the experimental control and presented as mean 6
SEM.
doi:10.1371/journal.pone.0013889.g008
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